LeMaitre Vascular, Inc. (NASDAQ:LMAT) insider David B. Roberts sold 48,317 shares of LeMaitre Vascular stock in a transaction on Friday, August 4th. The stock was sold at an average price of $33.12, for a total transaction of $1,600,259.04. Following the completion of the transaction, the insider now directly owns 30,105 shares of the company’s stock, valued at $997,077.60. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.
Shares of LeMaitre Vascular, Inc. (LMAT) opened at 33.96 on Friday. LeMaitre Vascular, Inc. has a one year low of $16.80 and a one year high of $36.09. The company’s 50-day moving average is $31.57 and its 200-day moving average is $27.77. The company has a market cap of $645.99 million, a price-to-earnings ratio of 48.51 and a beta of 0.65.
LeMaitre Vascular (NASDAQ:LMAT) last issued its quarterly earnings results on Thursday, July 27th. The medical instruments supplier reported $0.23 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.17 by $0.06. The business had revenue of $25.80 million for the quarter, compared to analysts’ expectations of $25.42 million. LeMaitre Vascular had a net margin of 14.19% and a return on equity of 15.02%. The business’s quarterly revenue was up 15.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.14 earnings per share. On average, equities analysts predict that LeMaitre Vascular, Inc. will post $0.80 EPS for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Thursday, September 7th. Stockholders of record on Wednesday, August 23rd will be given a dividend of $0.055 per share. The ex-dividend date is Monday, August 21st. This represents a $0.22 annualized dividend and a dividend yield of 0.65%. LeMaitre Vascular’s dividend payout ratio is presently 31.88%.
LeMaitre Vascular announced that its Board of Directors has initiated a stock buyback program on Thursday, July 27th that allows the company to buyback $7.50 million in outstanding shares. This buyback authorization allows the medical instruments supplier to buy up to 1.4% of its shares through open market purchases. Shares buyback programs are typically a sign that the company’s board believes its shares are undervalued.
TRADEMARK VIOLATION NOTICE: This article was first posted by BNB Daily and is the property of of BNB Daily. If you are accessing this article on another site, it was illegally copied and reposted in violation of United States and international copyright legislation. The legal version of this article can be read at https://www.baseball-news-blog.com/2017/08/19/david-b-roberts-sells-48317-shares-of-lemaitre-vascular-inc-nasdaqlmat-stock-updated.html.
LMAT has been the subject of several analyst reports. Benchmark Co. upgraded shares of LeMaitre Vascular from a “hold” rating to a “buy” rating in a report on Friday, July 28th. BidaskClub lowered shares of LeMaitre Vascular from a “strong-buy” rating to a “buy” rating in a report on Tuesday, July 25th. Canaccord Genuity lowered shares of LeMaitre Vascular from a “buy” rating to a “hold” rating and set a $28.00 target price for the company. in a report on Monday, July 10th. Zacks Investment Research upgraded shares of LeMaitre Vascular from a “hold” rating to a “buy” rating and set a $38.00 target price for the company in a report on Tuesday, August 1st. Finally, Craig Hallum started coverage on shares of LeMaitre Vascular in a report on Tuesday, June 6th. They issued a “hold” rating and a $31.00 target price for the company. Four investment analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. LeMaitre Vascular presently has an average rating of “Buy” and an average target price of $30.17.
Hedge funds have recently modified their holdings of the company. Columbia Wanger Asset Management LLC boosted its stake in shares of LeMaitre Vascular by 21.0% in the first quarter. Columbia Wanger Asset Management LLC now owns 1,093,903 shares of the medical instruments supplier’s stock valued at $26,943,000 after buying an additional 189,608 shares in the last quarter. Dimensional Fund Advisors LP boosted its stake in shares of LeMaitre Vascular by 4.4% in the second quarter. Dimensional Fund Advisors LP now owns 968,232 shares of the medical instruments supplier’s stock valued at $30,228,000 after buying an additional 40,767 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of LeMaitre Vascular by 23.5% in the second quarter. Vanguard Group Inc. now owns 815,580 shares of the medical instruments supplier’s stock valued at $25,462,000 after buying an additional 155,249 shares in the last quarter. Conestoga Capital Advisors LLC boosted its stake in shares of LeMaitre Vascular by 45.8% in the second quarter. Conestoga Capital Advisors LLC now owns 565,069 shares of the medical instruments supplier’s stock valued at $17,641,000 after buying an additional 177,379 shares during the period. Finally, State Street Corp boosted its stake in shares of LeMaitre Vascular by 25.2% in the second quarter. State Street Corp now owns 382,824 shares of the medical instruments supplier’s stock valued at $11,951,000 after buying an additional 77,009 shares during the period. 67.12% of the stock is currently owned by institutional investors and hedge funds.
LeMaitre Vascular Company Profile
LeMaitre Vascular, Inc is a provider of medical devices for the treatment of peripheral vascular disease. The Company develops, manufactures and markets medical devices and implants used primarily in the field of vascular surgery. It is engaged in the design, marketing, sales and technical support of medical devices and implants for the treatment of peripheral vascular disease industry segment.
Receive News & Ratings for LeMaitre Vascular Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular Inc. and related companies with MarketBeat.com's FREE daily email newsletter.